Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Thursday, July 23, 2026 1 min read
Key Takeaway: Genmab and AbbVie have clarified the primary endpoints of the Phase 3 EPCORE DLBCL-1 trial. This study evaluates the efficacy of epcoritamab, a T-cell engaging bispecific antibody, against standard chemoimmunotherapy options in patients with relapsed/refractory diffuse large B-cell lymphoma. The trial aims to provide insights into the treatment's effectiveness.
Market Sentiment Analysis
POSITIVE FACTORS
Clarification on primary endpoints enhances transparency.
Epcoritamab shows potential as a treatment option.
Collaboration between Genmab and AbbVie strengthens research.
Full Press Release Details
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults
Frequently Asked Questions
What is the focus of the EPCORE DLBCL-1 trial?
The trial focuses on evaluating epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
What are the primary endpoints of the trial?
Genmab and AbbVie clarified the primary endpoints, which compare epcoritamab to standard chemoimmunotherapy options.
What is epcoritamab?
Epcoritamab is a T-cell engaging bispecific antibody administered subcutaneously.
Who are the collaborators on this trial?
The trial is a collaboration between Genmab and AbbVie.